Tolerance and efficacy of intravenous iron saccharate for iron deficiency anemia in children and adolescents receiving long-term parenteral nutrition.

UNLABELLED The aim of this study was to evaluate the safety and efficacy of intravenous iron saccharate administration in iron-deficient anemic children, under long-term parenteral nutrition, who are unable to tolerate oral iron supplementation or are unresponsive to oral supplementation because of gastrointestinal dysfunction or iron malabsorption. METHODS Twenty-two infants and children aged 5 months-17 years (median: 38 months) receiving long-term parenteral nutrition and presenting with iron deficiency anemia were included. Total iron to be infused was determined by the formula: total iron (mg) = 0.6 x W (100 - Hb x 100/12) (W: weight, Hb: hemoglobin). Intravenous iron saccharate was given at the hospital. Each patient received a test dose of 25 mg of iron saccharate prior to the initiation of the infusion. Hemoglobin values, reticulocytes count, serum iron, and serum ferritin were determined before iron administration (day 1), as well as 15 and 45 days after iron administration. RESULTS Tolerance of intravenous iron saccharate was good except in one patient who developed transient exanthema and hypotension after completion of the last iron saccharate infusion. Intravenous iron led to a significative increase in hemoglobin concentration of 2.2 g/dl within 45 days (range: 0.4-4.3 g/dl). CONCLUSION Intravenous iron supplementation with iron saccharate is an efficient procedure, replenishing iron body stores and significantly increasing the hemoglobin concentration. The possible occurrence of allergic reactions emphasizes the need for close medical supervision.

[1]  M. Kearney,et al.  Compatibility and stability of additives in parenteral nutrition admixtures. , 1998, Nutrition.

[2]  R. D. Da Riol,et al.  Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants , 1998, Archives of disease in childhood. Fetal and neonatal edition.

[3]  W. Reinisch,et al.  Intravenous Iron and Erythropoietin for Anemia Associated with Crohn Disease , 1997, Annals of Internal Medicine.

[4]  D. Silverberg,et al.  Intravenous ferric saccharate as an iron supplement in dialysis patients. , 1996, Nephron.

[5]  O. Goulet,et al.  Iron overload in children receiving prolonged parenteral nutrition. , 1993, The Journal of pediatrics.

[6]  A. Zanella,et al.  Use of erythropoietin to increase the volume of autologous blood donated by orthopedic patients , 1993, Transfusion.

[7]  V. Kumpf,et al.  Parenteral Iron Dextran Therapy , 1990, DICP : the annals of pharmacotherapy.

[8]  H. J. Williams,et al.  Necrotic bilateral buttocks ulcerations occurring after multiple intramuscular iron dextran injections. , 1988, Archives of dermatology.

[9]  R. Lerner,et al.  Clinical use of the total dose intravenous infusion of iron dextran. , 1988, The Journal of laboratory and clinical medicine.

[10]  M. Reed,et al.  Use of intravenous iron dextran injection in children receiving total parenteral nutrition. , 1981, American journal of diseases of children.

[11]  R. Hamstra,et al.  Intravenous iron dextran in clinical medicine. , 1980, JAMA.

[12]  R. Salm,et al.  Intramuscular injections of iron compounds and oncogenesis in man , 1978, British medical journal.

[13]  D. Becroft,et al.  Intramuscular iron-dextran and susceptibility of neonates to bacterial infections. In vitro studies. , 1977, Archives of disease in childhood.

[14]  L. Hendeles,et al.  Guide to total dose intravenous iron dextran therapy. , 1974, American journal of hospital pharmacy.